All In Biotech

Drug Trial Radar · NCT05931042

Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review

Last checked: Nov 19, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,209

Actual

Start

Jun 1, 2023

Primary completion

Jun 15, 2023

Study completion Jun 18, 2023

Sponsor

Lead sponsor
Rawalpindi Medical CollegeAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 5, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this systematic review is to assess the effectiveness of neoadjuvant chemotherapy and Trastuzumab in achieving pathological complete response (pCR) in patients with HER2-positive breast cancer. The main questions it aims to answer are: * What is the overall rate of pathological complete response (pCR) in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy and Trastuzumab? * Are there any variations in the definition of pCR among the included trials? Participants in the selected clinical trials were HER2-positive breast cancer patients with non-metastatic operable, locally advanced, or inflammatory breast cancer. The main tasks participants were asked to do and the treatments they received are as follows: * Undergo neoadjuvant chemotherapy: Participants received chemotherapy treatment before their primary surgery. * Receive Trastuzumab: Participants were administered Trastuzumab, a targeted therapy for HER2-positive breast cancer. Researchers would compare the group of participants receiving neoadjuvant chemotherapy and Trastuzumab to other groups, if present, to see if there are differences in the rates of pathological complete response (pCR) or other effects.

Conditions

  • HER2+ Breast Cancer

Interventions

  • TrastuzumabDrug

    Trastuzumab was given at dosage of either 4mg/kg or 8mg/kg at mostly a weekly interval (but differs among the different studies)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathological Complete Response (pCR)Time frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rawalpindi Medical University

    Rawalpindi, Punjab Province, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.